中国肺癌杂志2011，Vol.14Issue(6)：497-501,5.DOI:10.3779/j.issn.1009-3419.2011.06.04
β-arrestin2在非小细胞肺癌患者血清中表达的临床意义
The Clinical Significance of β-arrestin 2 Expression in the Serum of Non-small Cell Lung Cancer Patients
摘要
Abstract
Background and objective Non-small cell lung cancer (NSCLC) with high morbidity and mortality is the most common types of lung cancer.beta-arrestin 2 is a kind of soluble protein regulating signal transduction mediated by G protein coupling receptor.The aim of this research is to evaluate the clinical significance of β-arrestin 2 expression in the serum of NSCLC patients.Methods The clinical and follow-up data of 20 healthy candidates and 67 patients diagnosed with NSCLC in Sun Yat-sen University Cancer Center from January 2005 to December 2006 was retrospectively analyzed.ELISA was applied to detect the expression of beta-arrestin 2.Results The serum level of β-arrestin 2 in NSCLC patients were all significally lower than those in healthy controls (P＜0.001, P＜0.001, P＜0.001).The serum level of β-arrestin 2 in stage Ⅰ NSCLC patients were higher than those in stage Ⅲ as well as in stage Ⅳ (P＜0.001, P＜0.001).No statistical difference of β-arrestin 2' serum level was found between with stage Ⅲ and stage Ⅳ patients (P=0.273).Univariate prognostic factor analyzed by KapLan-Meier method indicated patients' prognosis with high serum level of β-arrestin 2 was better than patients with low and middle (P＜0.001, P＜0.001).The serum level of β-arrestin 2 and the stage of NSCLC signally affected prognosis in COX regression model (P=0.003, P=0.004).Conclusion The serum level of β-arrestin 2 had significant difffrence between NSCLC patients and healthy controls, likewise between the early and advanced NSCLC patients.The serum level of β-arrestin 2 affected NSCLC patients' prognosis.关键词
β-arrestin 2/肺肿瘤/预后因素Key words
β-arrestin 2/ Lung neoplasms/ Prognostic factors分类
医药卫生引用本文复制引用
吴正清,童文侠,谭子辉,王思愚,林鹏..β-arrestin2在非小细胞肺癌患者血清中表达的临床意义[J].中国肺癌杂志,2011,14(6):497-501,5.基金项目
本研究受中山大学临床医学研究5010计划(No.200744)基金资助 （No.200744）
